Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531619 | 0.93 | HRH3 (0.77) | HRH3KDM4EALDH1A1HRH4BCHE | |
| SCHEMBL3531874 | 0.90 | HRH3 (0.78) | HRH3KDM4EALDH1A1ESR1MAPT | |
| SCHEMBL3532153 | 0.89 | HRH3 (0.70) | HRH3KDM4EALDH1A1HRH4 | |
| SCHEMBL3534462 | 0.89 | HRH3 (1.00) | HRH3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3531316 | 0.89 | HRH3 (0.80) | HRH3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3533980 | 0.88 | HRH3 (0.78) | HRH3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3535594 | 0.85 | HRH3 (0.66) | HRH3KDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3535705 | 0.83 | HRH3 (0.62) | HRH3BCHEACHEMAPT | |
| SCHEMBL3531242 | 0.83 | HRH3 (0.89) | HRH3LTA4HMEN1KMT2AESR1 | |
| SCHEMBL3534207 | 0.83 | HRH3 (0.67) | HRH3KDM4EALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747203-A4 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | claimed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | claimed |
| EP-1747203-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | claimed |
| WO-2005110998-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | claimed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | claimed |
| US-7807837-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-04 | — | — | US | disclosed |
| EP-1747203-A4 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| EP-1373218-B9 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL JANSSEN PHARM (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1373218-B1 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7265135-B2 | 2-oxy, 2-amino, and 2-thio-imidazole compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1747203-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005110998-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20040147577-A1 | Heterocyclic compounds | BOGENSTAETTER MICHAEL (GB) | 2004-07-29 | — | — | US | disclosed |
| EP-1373218-A1 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | Ortho McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020198237-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002079168-A1 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | ABL1, NOS2, FLT3 | HRH3 2308/4885KDM4E 838/4885ALDH1A1 2343/4885 |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | ABL1, NOS2, FLT3 | HRH3 2308/4885KDM4E 838/4885ALDH1A1 2343/4885 |
| US-20020198237-A1 | Heterocyclic compounds | HRH2, HRH4, HRH1 | HRH3 4/4885KDM4E 3867/4885ALDH1A1 1526/4885 |
| US-20040147577-A1 | Heterocyclic compounds | HRH2, HRH4, HRH1 | HRH3 4/4885KDM4E 3867/4885ALDH1A1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.